COVID19 infection and vaccination and the risk of pituitary apoplexy: an entangled yarn
- PMID: 39433700
- DOI: 10.1007/s12020-024-04078-7
COVID19 infection and vaccination and the risk of pituitary apoplexy: an entangled yarn
Abstract
Purpose: Pituitary apoplexy (PA) has been increasingly reported in association with both infection from and vaccination for COVID19. Our aim was to analyse the available published cases and compare the clinical characteristics in the two groups (infection vs vaccination).
Methods: We systematically reviewed the published literature for all cases of PA associated with COVID19 infection or vaccination. We also presented two cases managed at our Centre.
Results: Collectively, fortythree cases were analysed. Patients with PA after COVID19 vaccination (n = 7), compared with patients with PA after COVID19 infection (n = 36), were significantly younger (p = 0.009) and had a more abrupt onset of PA (p = 0.022), but showed a milder hormonal involvement (p = 0.008) and a lower rate of persistent hypopituitarism during follow-up (p = 0.001). Patients in the vaccination group did not have clinical risk factors for PA, although this difference did not reach statistical significance.
Conclusions: PA associated with COVID19 is a rare but clinically significant entity, although pathophysiological details of this association are lacking. Given the significantly different clinical presentation, we could speculate that PA induced by COVID19 vaccination might represent a distinct clinical entity, with different pathophysiological mechanism, compared to PA from COVID19 infection.
Keywords: COVID19; COVID19 vaccine; Hypophysis; Hypopituitarism; Pituitary gland; Transsphenoidal surgery.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Compliance with ethical standards. Conflict of interest: The authors declare no competing interests. Ethics approval: The study was conducted in accordance with the Declaration of Helsinki. The patients included in the manuscript provided their written informed consent for publication.
References
-
- Z.C. Hannoush, R.E. Weiss “Pituitary Apoplexy.,” In: Feingold K.R., Anawalt B., Blackman M.R., Boyce A., Chrousos G., Corpas E., de Herder W.W., Dhatariya K., Dungan K., Hofland J., et al., editors. Endotext. South Dartmouth [MA]: MDText.com, Inc. [2018] http://www.ncbi.nlm.nih.gov/books/NBK279125/ [Accessed June 22, 2024]
-
- N. Muthukumar, Pituitary apoplexy: A comprehensive review. Neurol. India 68, S72–S78 (2020). https://doi.org/10.4103/0028-3886.287669 - DOI - PubMed
-
- B. Biagetti, R. Simò, Pituitary apoplexy: Risk factors and underlying molecular mechanisms. Int. J. Mol. Sci. 23, 8721 (2022). https://doi.org/10.3390/ijms23158721 - DOI - PubMed - PMC
-
- C. Hazzi, N. Villemure-Poliquin, S. Nadeau, P.-O. Champagne, SARS-CoV-2 infection, a risk factor for pituitary apoplexy? A case series and literature review. Ear Nose Throat J. 103, 153S–161S (2024). https://doi.org/10.1177/01455613231179714 - DOI - PubMed
-
- K.A. Aghdam, Z.-A. Abtahi, S.A. Sonbolestan, M.S. Sanjari, Pituitary apoplexy secondary to thrombocytopenia due to severe acute respiratory syndrome coronavirus 2 infection: report of a rare case and literature review. J. Curr. Ophthalmol. 34, 364–368 (2022). https://doi.org/10.4103/joco.joco_321_21 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
